share_log

JonesTrading Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $12

Benzinga Real-time News ·  Jul 15, 2021 09:32

JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment